In contrast to its anti-inflammatory and anti-apoptotic peripheral effect, levosimendan failed to induce a long-term neuroprotective effect in a rat model of mild septic encephalopathy: A pilot study

Neuroscience Letters

Volumn 560, Issue , 2014, Pages 117-121

  Plaschke, Konstanze ^a   Bent, Franziska ^a   Wagner, Sören ^a   Zorn, Markus ^b   Kopitz, Jürgen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cognition; Endotoxinemia; Inflammation; Levosimendan; LPS; Neuroprotection

Indexed keywords

CORTICOSTERONE; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEVOSIMENDAN; LIPOPOLYSACCHARIDE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; BRAIN DISEASE; BRAIN TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTOXEMIA; HOLE BOARD TEST; MALE; MILD SEPTIC ENCEPHALOPATHY; MORRIS WATER MAZE TEST; NEUROPROTECTION; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOMETRY; RAT; REDUCTION; SPLEEN;

COGNITION; ENDOTOXINEMIA; INFLAMMATION; LEVOSIMENDAN; LPS; NEUROPROTECTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BRAIN; COGNITION DISORDERS; CORTICOSTERONE; CYTOKINES; ENDOTOXEMIA; HYDRAZONES; LIPOPOLYSACCHARIDES; MALE; MAZE LEARNING; NEUROPROTECTIVE AGENTS; PILOT PROJECTS; PYRIDAZINES; RATS, WISTAR; SPLEEN; TIME FACTORS;

EID: 84891675441     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.12.021     Document Type: Article

References (31)

1. Antila S., Pesonen U., Lehtonen L., Tapanainen P., Nikkanen H., Vaahtera K., Scheinin H. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur. J. Pharm. Sci. 2004, 23:213-222.
2. Banks W.A., Robinson S.M. Minimal penetration of lipopolysaccharide across the murine blood-brain barrier. Brain Behav. Immun. 2010, 24:102-109.
3. Brun-Buisson C., Doyon F., Carlet J., Dellamonica P., Gouin F., Lepoutre A., Mercier J.C., Offenstadt G., Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU group for severe sepsis. JAMA 1995, 274:968-974.
4. Buckley J.F., Singer M., Clapp L.H. Role of KATP channels in sepsis. Cardiovasc. Res. 2006, 72:220-230.
5. Ertel W., Faist E., Nestle C., Hueltner L., Storck M., Schildberg F.W. Kinetics of interleukin-2 and interleukin-6 synthesis following major mechanical trauma. J. Surg. Res. 1990, 48:622-628.
6. Hagiwara S., Iwasaka H., Hasegawa A., Oyama M., Imatomi R., Uchida T., Noguchi T. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock 2011, 35:289-292.
7. Hein M., Roehl A.B., Baumert J.H., Scherer K., Steendijk P., Rossaint R. Anti-ischemic effects of inotropic agents in experimental right ventricular infarction. Acta Anaesthesiol. Scand. 2009, 53:941-948.
8. Iacobone E., Bailly-Salin J., Polito A., Friedman D., Stevens R.D., Sharshar T. Sepsis-associated encephalopathy and its differential diagnosis. Crit. Care Med. 2009, 37:S331-S336.
9. Iwata A., de Claro R.A., Morgan-Stevenson V.L., Tupper J.C., Schwartz B.R., Liu L., Zhu X., Jordan K.C., Winn R.K., Harlan J.M. Extracellular administration of BCL2 protein reduces apoptosis and improves survival in a murine model of sepsis. PLoS One 2011, 6:e14729.
10. Jacob A., Brorson J.R., Alexander J.J. Septic encephalopathy: inflammation in man and mouse. Neurochem. Int. 2011, 58:472-476.
11. Kafa I.M., Uysal M., Bakirci S., Ayberk K.M. Sepsis induces apoptotic cell death in different regions of the brain in a rat model of sepsis. Acta Neurobiol. Exp. (Wars) 2010, 70:246-260.
12. Kaptan K., Erinc K., Ifran A., Yildirim V., Uzun M., Beyan C., Isik E. Levosimendan has an inhibitory effect on platelet function. Am. J. Hematol. 2008, 83:46-49.
13. Kivikko M., Antila S., Eha J., Lehtonen L., Pentikainen P.J. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int. J. Clin. Pharmacol. Ther. 2002, 40:465-471.
14. MacDonald P.E., De Marinis Y.Z., Ramracheya R., Salehi A., Ma X., Johnson P.R., Cox R., Eliasson L., Rorsman P. A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol. 2007, 5:e143.
15. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11:47-60.
16. O'Reilly B., Vander A.J., Kluger M.J. Effects of chronic infusion of lipopolysaccharide on food intake and body temperature of the rat. Physiol. Behav. 1988, 42:287-291.
17. Pan W., Kastin A.J. Interactions of cytokines with the blood-brain barrier: implications for feeding. Curr. Pharm. Des. 2003, 9:827-831.
18. Plaschke K., Feindt J., Djuric Z., Heiland S., Autschbach F., Lewicka S., Martin E., Bardenheuer H.J., Nawroth P.P., Bierhaus A. Chronic corticosterone-induced deterioration in rat behaviour is not paralleled by changes in hippocampal NF-kappaB-activation. Stress 2006, 9:97-106.
19. Plaschke K., Staub J., Ernst E., Marti H.H. VEGF overexpression improves mice cognitive abilities after unilateral common carotid artery occlusion. Exp. Neurol. 2008, 214:285-292.
20. Plaschke K., Yun S.W., Martin E., Hoyer S., Bardenheuer H.J. Interrelation between cerebral energy metabolism and behaviour in a rat model of permanent brain vessel occlusion. Brain Res. 1999, 830:320-329.
21. Roehl A.B., Hein M., Loetscher P.D., Rossaint J., Weis J., Rossaint R., Coburn M. Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury. BMC Neurol. 2010, 10:97.
22. Scheiermann P., Ahluwalia D., Hoegl S., Dolfen A., Revermann M., Zwissler B., Muhl H., Boost K.A., Hofstetter C. Effects of intravenous and inhaled levosimendan in severe rodent sepsis. Intensive Care Med. 2009, 35:1412-1419.
23. Semmler A., Frisch C., Debeir T., Ramanathan M., Okulla T., Klockgether T., Heneka M.T. Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. Exp. Neurol. 2007, 204:733-740.
24. Semmler A., Hermann S., Mormann F., Weberpals M., Paxian S.A., Okulla T., Schafers M., Kummer M.P., Klockgether T., Heneka M.T. Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J. Neuroinflammation 2008, 5:38.
25. Sparkman N.L., Martin L.A., Calvert W.S., Boehm G.W. Effects of intraperitoneal lipopolysaccharide on Morris maze performance in year-old and 2-month-old female C57BL/6J mice. Behav. Brain Res. 2005, 159:145-151.
26. Taniguchi T., Takagi D., Takeyama N., Kitazawa Y., Tanaka T. Platelet size and function in septic rats: changes in the adenylate pool. J. Surg. Res. 1990, 49:400-407.
27. Uberti F., Caimmi P.P., Molinari C., Mary D., Vacca G., Grossini E. Levosimendan modulates programmed forms of cell death through K(ATP) channels and nitric oxide. J. Cardiovasc. Pharmacol. 2011, 57:246-258.
28. Wüppen K., Oesterle D., Lewicka S., Kopitz J., Plaschke K. A subchronic application period of glucocorticoids leads to rat cognitive dysfunction whereas physostigmine induces a mild neuroprotection. J. Neural Transm. 2010, 117:1055-1065.
29. Yamada K., Ji J.J., Yuan H., Miki T., Sato S., Horimoto N., Shimizu T., Seino S., Inagaki N. Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. Science 2001, 292:1543-1546.
30. Zacharowski K., Zacharowski P.A., Koch A., Baban A., Tran N., Berkels R., Papewalis C., Schulze-Osthoff K., Knuefermann P., Zahringer U., Schumann R.R., Rettori V., McCann S.M., Bornstein S.R. Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6392-6397.
31. Zhou M., Wu R., Dong W., Leong J., Wang P. Accelerated apoptosis contributes to aging-related hyperinflammation in endotoxemia. Int. J. Mol. Med. 2010, 25:929-935.